Nephrocare IPO Day 2: Subscription Crosses 25%! Grey Market Premium Hints at Strong Listing!

IPO
Whalesbook Logo
AuthorAarav Shah|Published at:
Nephrocare IPO Day 2: Subscription Crosses 25%! Grey Market Premium Hints at Strong Listing!
Overview

Nephrocare Health Services' IPO is seeing steady demand, subscribing 25% on day two (December 11). The Rs 871-crore issue has garnered bids for over 33 lakh shares. The company secured Rs 260 crore from anchor investors. With a Grey Market Premium (GMP) of Rs 20, investors anticipate a positive debut.

Nephrocare Health Services IPO: Day 2 Subscription Update

Nephrocare Health Services, a prominent player in the dialysis services sector, has reported a subscription of 25% for its Initial Public Offering (IPO) on the second day of its share sale, which commenced on December 11.

IPO Subscription Figures

  • The Rs 871-crore initial public offering (IPO) has so far received bids for 33,11,968 shares against the total 1,33,87,854 shares on offer, according to data from the National Stock Exchange (NSE).
  • The portion reserved for retail individual investors (RIIs) has been subscribed 27%.
  • The quota for Non-Institutional Investors (NIIs) saw a subscription of 11%.
  • Qualified institutional buyers (QIBs) have bid for 30% of the shares allocated to them.

Anchor Investors and Pre-IPO Activity

  • Nephrocare Health Services, known for its brand NephroPlus, announced on Tuesday that it had successfully garnered Rs 260 crore from anchor investors.
  • This follows secondary transactions totaling Rs 136 crore concluded on December 8-9. These deals provided partial liquidity to early shareholders, including Quadria Capital, Bessemer Venture Partners, Investcorp, and promoter-linked entities.
  • Key investors such as Think Investments' TIMF Holdings, Axis Max Life Insurance, Akash Bhaisali, Malabar India Fund, and Motilal Oswal India Excellence Fund participated in these pre-IPO secondary transactions.

IPO Details and Fund Utilization

  • The Hyderabad-based company's IPO is set to conclude on December 12.
  • The company has fixed a price band of Rs 438 to Rs 460 per share, valuing the company at over Rs 4,600 crore.
  • The IPO comprises a fresh issue of shares worth Rs 353.4 crore and an Offer For Sale (OFS) of 1.12 crore shares valued at Rs 517.6 crore at the upper end, bringing the total issue size to Rs 871 crore.
  • Proceeds from the fresh issue are earmarked for opening new dialysis clinics in India (Rs 129.1 crore), repayment of debt (Rs 136 crore), and general corporate purposes.
  • Promoters including Investcorp Private Equity Fund II and Healthcare Parent, along with other shareholders like International Finance Corporation, will offload their stakes through the OFS.

Company Background and Financials

  • Incorporated in 2009, NephroPlus is a significant player in the dialysis care market.
  • As of September 30, 2025, it operated a global network of 519 clinics, with 51 located internationally in the Philippines, Uzbekistan, and Nepal.
  • In fiscal 2024, the company expanded into Saudi Arabia through a joint venture.
  • The company operates 165-bed dialysis clinic in Tashkent, Uzbekistan, which is claimed to be the largest globally.
  • NephroPlus boasts an extensive pan-India network of clinics across 288 cities, covering 21 states and 4 union territories, with 77% of its clinics situated in tier II and tier III cities.
  • For fiscal year 2025, NephroPlus reported revenue from operations of Rs 756 crore and a profit after tax of Rs 67 crore.

Grey Market Premium (GMP) Insight

  • According to InvestorGain, the Grey Market Premium (GMP) for Nephrocare Health Services stood at Rs 20 as of December 11.
  • Based on the upper price band of Rs 460, this GMP suggests an estimated listing price of Rs 480 per share.
  • This indicates an expected percentage gain of approximately 4.35% on listing.

Importance of the Event

  • The subscription rate provides a real-time gauge of investor demand and confidence in the company's prospects.
  • A healthy subscription level is crucial for a successful IPO debut.
  • The GMP offers an unofficial indicator of market sentiment and potential listing gains.

Future Expectations

  • Investors will be keenly watching the final subscription numbers by the IPO closing date on December 12.
  • NephroPlus is scheduled to make its stock market debut on December 17.
  • The company's ability to execute its expansion plans will be key to its long-term growth.

Market Reaction

  • The current subscription levels and positive GMP suggest a generally positive initial reception from investors.

Impact

  • For retail investors, a successful IPO listing could offer immediate returns.
  • The expansion funded by the IPO is expected to bolster NephroPlus's market position in the growing healthcare services sector.
  • The company's performance post-listing will be an important benchmark for other healthcare providers.
  • Impact Rating: 7/10

Difficult Terms Explained

  • IPO (Initial Public Offering): The process by which a private company offers its shares to the public for the first time, typically to raise capital.
  • Grey Market Premium (GMP): An unofficial indicator reflecting the demand for an IPO's shares in the grey market before its official listing. A positive GMP suggests demand.
  • RIIs (Retail Individual Investors): Individual investors who apply for shares up to a specified limit (usually Rs 2 lakh).
  • NIIs (Non-Institutional Investors): Investors who bid for shares exceeding the RII limit but are not large financial institutions; this category includes high-net-worth individuals and corporations.
  • QIBs (Qualified Institutional Buyers): Large institutional investors such as mutual funds, foreign institutional investors, insurance companies, and banks that are eligible to invest substantial amounts.
  • Anchor Investors: Institutional investors who commit to purchasing a significant portion of an IPO's shares before the public offering begins, providing a floor of demand and stability.
  • OFS (Offer For Sale): A component of an IPO where existing shareholders sell their shares to new investors, rather than the company issuing new shares to raise funds.
  • Fresh Issue: The creation and sale of new shares by the company itself during an IPO to raise capital, which increases the total number of outstanding shares.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.